NEXT MDVN IN THE MAKING HERE ...A LIFETIME OPP AT CURRENT LEVEL !!
Blockbuster Thermodox (Liver Cancer) Phase 3 results coming next Quarter .80% CHANCE THAT PHASE 3 WILL BE SUCCESSFUL MEANS THIS LOW FLOAT STOCK WILL EXPLODE INTO HIGH DOUBLE DIGITS LIKE MDVN . Market Cap of 60 Million is really a big joke . Big Partner Deal for Europe coming any day now means HUGE UPFRONT PAYMENTS FOR CLSN .
Celsion (CLSN) will have 2 Potential Blockbuster on the Market within 15 months .CLSN will be the next Billion Dollar Company .
Brean Murray Carret & Co. Starts Celsion Corp (CLSN) at Buy; Expectiing Positive Phase 3 Data This Year February 16, 2012 7:37 AM EST
Brean Murray Carret & Co. initiates coverage on Celsion Corp (NASDAQ: CLSN) with a Buy. PT $7.00.
Brean analyst says, "We believe ThermoDox will be broadly adopted once it is approved. Due to the potential ability of ThermoDox to reduce the recurrence rate in intermediate HCC patients, we are optimistic about its adoption as the future standard of care, especially given how seamlessly ThermoDox can be integrated with RFA. Its effectiveness should increase the number of RFA procedures and enable the RFA/ThermoDox combination to take market share from procedures like TACE with chemotherapy. We view the use of an approved active agent (doxorubicin) as a risk mitigating factor for Celsion."